This VC firm focuses on investing in early-stage companies with a strong social impact, particularly in education and environmental sustainability.
https://twitter.com/PaloSantoFund
Key people at Palo Santo VC.
Palo Santo is a venture capital firm dedicated to investing in early-stage companies that develop psychedelic therapeutics and technologies aimed at addressing the global mental health crisis. Their mission centers on advancing innovative solutions in mental health, particularly through psychedelic medicines, digital therapeutics, biopharma, and healthcare services. The firm’s investment philosophy emphasizes backing companies that are poised to create a paradigm shift in psychiatry by offering rapid, durable treatments for conditions such as depression, PTSD, anxiety, addiction, and neurodegenerative diseases. Palo Santo’s portfolio includes over 20 companies, reflecting a strong focus on clinical development, FDA approval, and expanding patient access to these emerging therapies. Their impact on the startup ecosystem lies in providing not only capital but also strategic support, connecting founders with experts and fostering collaboration within the psychedelic medicine space[1][2][3][4].
Founded in 2021, Palo Santo was established by co-founders Tim Schlidt, Daniel Goldberg, Tony Eisenberg, and Zack Lomis, who bring backgrounds in healthcare investing, private equity, and strategic finance. The idea emerged from recognizing the untapped potential of psychedelics to revolutionize mental health treatment amid a growing global crisis and a lack of institutional capital in this fragmented emerging sector. Early traction included raising an initial $35 million fund, which later expanded to $50 million, and quickly building a portfolio of more than 20 companies. The founders leveraged their combined expertise and networks to position Palo Santo as a diligent, validating investor deeply engaged in the science and commercial development of psychedelic therapies[2][3][7].
Palo Santo is riding the wave of destigmatization, medicalization, and legalization of psychedelics, which is transforming mental healthcare. The timing is critical as traditional psychiatric treatments have seen little innovation for decades, and there is a growing global mental health crisis demanding new solutions. Market forces such as increasing FDA support, expanding scientific evidence, and rising patient demand favor the growth of psychedelic therapeutics. By strategically investing in and supporting companies across the drug development and digital health spectrum, Palo Santo influences the broader ecosystem by accelerating the commercialization and adoption of these novel therapies, helping to establish psychedelics as a future standard of care[1][2][3].
Looking ahead, Palo Santo is likely to continue expanding its fund size and portfolio, deepening its role as a key player in the psychedelic investment space. Trends shaping their journey include ongoing regulatory progress, increasing clinical validation, and broader acceptance of mental health innovations. Their influence may evolve from primarily capital provider to ecosystem builder, driving partnerships and cross-company collaboration to scale impact. As the psychedelic medicine field matures, Palo Santo’s early and focused involvement positions it to shape the future of mental health treatment and create significant value for investors, patients, and society at large[1][7][8].
Key people at Palo Santo VC.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 1, 2021 | wavepaths | $5.0M Seed | — | 500 Startups, 500 Global |
